Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Indaptus Therapeutics, Inc. (INDP) since 2021 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Indaptus Therapeutics, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1857044.
Total stock buying since 2021: $492,865.
Total stock sales since 2021: $100,042.
Total stock option exercises since 2021: $0.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2023 | 103,352 | $216,386 | 0 | $0 | 0 | $0 |
| 2022 | 51,027 | $127,371 | 20,000 | $100,042 | 0 | $0 |
| 2021 | 23,187 | $149,108 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2023-08 | 103,352 | $216,386 | 0 | $0 | 0 | $0 |
| 2022-12 | 500 | $935 | 0 | $0 | 0 | $0 |
| 2022-11 | 10,500 | $19,860 | 0 | $0 | 0 | $0 |
| 2022-09 | 20,150 | $54,025 | 0 | $0 | 0 | $0 |
| 2022-06 | 19,727 | $51,882 | 0 | $0 | 0 | $0 |
| 2022-03 | 50 | $204 | 0 | $0 | 0 | $0 |
| 2022-02 | 0 | $0 | 14,130 | $70,692 | 0 | $0 |
| 2022-01 | 100 | $465 | 5,870 | $29,350 | 0 | $0 |
| 2021-11 | 11,187 | $65,108 | 0 | $0 | 0 | $0 |
| 2021-09 | 12,000 | $84,000 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2023-08-14 | Anderson Glen R. | Buy | 23,934 | 2.34 | 56,005 |
| 2023-08-11 | Anderson Glen R. | Buy | 35,064 | 2.12 | 74,335 |
| 2023-08-10 | Anderson Glen R. | Buy | 44,354 | 1.94 | 86,046 |
| 2022-12-01 | Litchev Boyan Vesselinov (Chief Medical Officer) | Buy | 500 | 1.87 | 935 |
| 2022-11-22 | Litchev Boyan Vesselinov (Chief Medical Officer) | Buy | 500 | 1.83 | 915 |
| 2022-11-21 | Meckler Jeffrey A (CEO and Director) | Buy | 9,600 | 1.90 | 18,240 |
| 2022-11-18 | Meckler Jeffrey A (CEO and Director) | Buy | 400 | 1.76 | 705 |
| 2022-09-08 | Meckler Jeffrey A (CEO and Director) | Buy | 10,308 | 2.80 | 28,862 |
| 2022-09-07 | Linscott Walt Addison (Chief Business Officer) | Buy | 150 | 2.62 | 393 |
| 2022-09-07 | Meckler Jeffrey A (CEO and Director) | Buy | 8,632 | 2.57 | 22,184 |
| 2022-09-06 | Meckler Jeffrey A (CEO and Director) | Buy | 1,060 | 2.44 | 2,586 |
| 2022-06-06 | Meckler Jeffrey A (CEO and Director) | Buy | 19,727 | 2.63 | 51,882 |
| 2022-03-02 | Litchev Boyan Vesselinov (Chief Medical Officer) | Buy | 50 | 4.09 | 204 |
| 2022-02-01 | Newman Michael James (CSO and Director) | Sale | 14,130 | 5.00 | 70,692 |
| 2022-01-31 | Litchev Boyan Vesselinov (Chief Medical Officer) | Buy | 100 | 4.65 | 465 |
| 2022-01-31 | Newman Michael James (CSO and Director) | Sale | 5,870 | 5.00 | 29,350 |
| 2021-11-18 | Meckler Jeffrey A (CEO and Director) | Buy | 11,187 | 5.82 | 65,108 |
| 2021-09-14 | Meckler Jeffrey A (CEO and Director) | Buy | 12,000 | 7.00 | 84,000 |
Insider trading activities including stock purchases, stock sales, and option exercises of INDP listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Indaptus Therapeutics, Inc. (symbol INDP, CIK number 1857044) see the Securities and Exchange Commission (SEC) website.